reported a functional CAF subset in BC, known as interferon‐regulated CAF, which enhances tumor stemness and mediates chemotherapy resistance by secreting WNT5A and interacting with tumor cells.[22] Targeting CAFs has shown the potential to improve chemotherapy sensitivity and reduce tumor recurrence.[6, 23, 24] Nonetheless, the heterogeneity of CAFs between primary and recurrent BC and the underlying mechanisms of BC recurrence are not fully understood. This evidence concerns the gene WNT5A and breast cancer.